
**International Journal of Innovative Technologies in Social Science**

e-ISSN: 2544-9435

**Operating Publisher**
**SciFormat Publishing Inc.**
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

| | |
|---|---|
| **ARTICLE TITLE** | THE SOCIO-CLINICAL IMPACT OF GLP-1 RECEPTOR AGONISTS ON ORAL HEALTH: BRIDGING THE BIOPSYCHOSOCIAL GAP THROUGH DIGITAL HEALTH TECHNOLOGIES |
| **DOI** | https://doi.org/10.31435/ijitss.2(50).2026.5572 |
| **RECEIVED** | 10 March 2026 |
| **ACCEPTED** | 15 June 2026 |
| **PUBLISHED** | 23 June 2026 |
| **LICENSE** | The article is licensed under a **Creative Commons Attribution 4.0 International License.** |

# THE SOCIO-CLINICAL IMPACT OF GLP-1 RECEPTOR AGONISTS ON ORAL HEALTH: BRIDGING THE BIOPSYCHOSOCIAL GAP THROUGH DIGITAL HEALTH TECHNOLOGIES

***Marta Krzyżanowska*** *(Corresponding Author, Email: krzyzanowska6@gmail.com)*
*Mix-Med Arima Private Healthcare Institution, Radom, Poland*
*ORCID ID: 0009-0001-2932-0337*

***Natalia Smyczyńska***
*Independent Public Outpatient Healthcare Center Warsaw Praga-Północ, Warsaw, Poland*
*ORCID ID: 0009-0008-8213-3531*

***Natasza Jankowska***
*Specialized Dental Clinic, 5th Military Clinical Hospital with Polyclinic – Independent Public Healthcare Institution, Krakow, Poland*
*ORCID ID: 0009-0009-0491-3716*

***Sebastian Trochim***
*GA-MED Private Healthcare Institution, Lublin, Poland*
*ORCID ID: 0009-0009-5555-6173*

***Mikołaj Kubik***
*Independent Public Outpatient Healthcare Center Warsaw Praga-Północ, Warsaw, Poland*
*ORCID ID: 0009-0002-5875-4713*

***Kacper Curzytek***
*University Clinical Hospital No. 1, Lublin, Poland*
*ORCID ID: 0009-0006-3049-0188*

**ABSTRACT**

The exponential global adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for metabolic management has inadvertently unmasked a secondary crisis within the oral-systemic axis. This systematic review aims to synthesize the clinical pathophysiology of GLP-1 RA-induced oral dysfunction and evaluate its broader biopsychosocial and economic impacts, proposing digital health interventions as a mitigating framework. Utilizing a multi-stage search strategy across PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library (up to 2025), 34 out of 142 screened sources were selected for high-level synthesis. Findings indicate that GLP-1 RAs disrupt salivary homeostasis by down-regulating aquaporin-5 and inducing secondary gastroesophageal reflux, precipitating rapid perimylolysis, xerostomia, and dysgeusia. Beyond physiological damage, this localized deterioration acts as a severe psychosocial stressor, driving social isolation, elevated anxiety, and occupational presenteeism, fundamentally altering the depreciation rate of the patient's "Health Capital". The current siloed architecture of medical and dental care fails to address this multifaceted burden. The review concludes that a paradigm shift toward Value-Based Healthcare is imperative. By embedding digital health interventions—such as continuous Internet of Things (IoT) salivary biomonitoring, Artificial Intelligence (AI) diagnostic screening, and teledentistry—into a mandatory "Diabeto-Dental Care Pathway," reactive interventions can be replaced with proactive prevention. Bridging the medical-dental divide through technology and enhanced eHealth literacy is essential to safeguard the socio-economic vitality of patients undergoing incretin therapies.

**KEYWORDS**

GLP-1 Receptor Agonists, Xerostomia, Artificial Intelligence Diagnostics, Health Literacy, Socio-Economic Productivity, Quality of Life (QoL)

**CITATION**

Marta Krzyżanowska, Natalia Smyczyńska, Natasza Jankowska, Sebastian Trochim, Mikołaj Kubik, Kacper Curzytek. (2026) The Socio-Clinical Impact of GLP-1 Receptor Agonists on Oral Health: Bridging the Biopsychosocial Gap Through Digital Health Technologies. *International Journal of Innovative Technologies in Social Science*. 2(50). doi: 10.31435/ijitss.2(50).2026.5572



## 1. Introduction: The Metabolic Revolution and the Biopsychosocial Gap in Oral Health

Modern healthcare is currently navigating an unprecedented global pandemic of metabolic dysregulation. The escalating prevalence of obesity and type 2 diabetes mellitus (T2DM) has reached a critical threshold, necessitating a profound paradigm shift in therapeutic delivery and chronic disease management [1]. Within this context, the emergence and mass-scale adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—most notably semaglutide and tirzepatide—have fundamentally altered the clinical landscape. These pharmacological agents offer a historically unprecedented "triple threat" of clinical efficacy: robust glycemic control, significant and sustained weight reduction, and profound cardiovascular and renal protection [2, 3]. Consequently, GLP-1 RAs have rapidly transitioned from specialized endocrinological treatments to globally ubiquitous blockbuster medications.

However, as the administration of these agents scales exponentially across diverse global populations, a critical oversight within the current medical and social discourse is becoming increasingly apparent: the profound, iatrogenic impact on the oral-systemic axis. While the systemic metabolic benefits of incretin therapies are widely celebrated and meticulously monitored, their localized adverse effects within the oral cavity remain largely marginalized. Emerging clinical evidence indicates that GLP-1 RAs actively disrupt salivary homeostasis, precipitating severe hyposalivation, accelerated dental perimylolysis (erosion) triggered by secondary gastroesophageal reflux, and dysgeusia [4, 5]. In traditional, fragmented models of healthcare, these stomatological manifestations are frequently dismissed as minor, non-life-threatening inconveniences.

Yet, within the context of interdisciplinary health sciences—and particularly through the lens of the *International Journal of Innovative Technologies in Social Science*—it is imperative to recognize that oral health transcends mere anatomical integrity. Viewed through the foundational Biopsychosocial Model proposed by George Engel [6], the oral cavity is a highly complex interface intrinsically linked to an individual's psychological stability and social integration. The sudden onset of unbuffered dental deterioration, persistent halitosis, and sensory disruption acts as a severe secondary psychosocial stressor for patients already navigating the complex stigmas of metabolic syndrome. Furthermore, from a macroeconomic perspective, chronic dental pain and aesthetic degradation are leading drivers of occupational presenteeism, significantly depleting a patient's "Health Capital" and diminishing overall socio-economic productivity [7].

The fundamental premise of this review is that the current "siloed" approach to metabolic management—where diabetology and dentistry operate independently—is no longer sustainable or ethical in the era of GLP-1 RAs. To mitigate the localized destruction caused by these revolutionary drugs, the medical community must leverage the burgeoning ecosystem of digital health. Innovative technologies, such as mobile health (mHealth) biomonitoring, Artificial Intelligence (AI) diagnostic algorithms, and teledentistry, possess the unique capacity to bridge the historical divide between the physician's office and the dental chair [8]. By embedding these socio-technological solutions into standard treatment protocols, reactive dental interventions can be replaced by proactive, integrated algorithmic prevention.

Therefore, this review aims to critically synthesize the clinical pathophysiology of GLP-1 RA-induced oral dysfunction with the advanced frameworks of digital health and social science. To address this intersectional challenge and redefine the standard of care for the modern metabolic patient, this analysis is guided by the following primary Research Questions (RQs):

- **RQ1:** What are the primary pathophysiological mechanisms through which GLP-1 RAs precipitate stomatological deterioration, and how do these clinical manifestations translate into psychosocial distress and diminished quality of life?

- **RQ2:** In what ways does the localized degradation of the oral cavity impact broader socio-economic metrics, specifically regarding health capital depreciation and occupational presenteeism?
- **RQ3:** How can the strategic deployment of digital health interventions—including Internet of Things (IoT) biomonitoring, Artificial Intelligence diagnostics, and teledentistry—bridge the historical medical-dental divide to establish a proactive, Value-Based Healthcare framework?

By systematically addressing these questions, this paper seeks to provide policymakers, technologists, and clinicians with a cohesive blueprint for safeguarding the socio-economic vitality of patients undergoing life-altering incretin therapies.

## 2. Methodology

This systematic review was conducted with conceptual alignment to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to ensure a rigorous, transparent, and replicable methodological framework. A comprehensive, multi-stage literature search was executed across four primary electronic databases: PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library. The search encompassed literature published from database inception up to January 2025. To capture the intersectional nature of the research questions, the search strategy employed a combination of Medical Subject Headings (MeSH) and free-text terms, utilizing Boolean operators (AND, OR). The core search string included: ("GLP-1 receptor agonists" OR "semaglutide" OR "tirzepatide") AND ("xerostomia" OR "oral health" OR "perimylolysis" OR "dental erosion") AND ("mHealth" OR "digital health interventions" OR "teledentistry" OR "AI in dentistry") AND ("socio-economic impact" OR "health capital" OR "patient-reported outcomes" OR "PROs").

To ensure the synthesis was grounded in high-quality, relevant literature, specific inclusion and exclusion criteria were established *a priori*. The inclusion criteria were intentionally broadened beyond traditional clinical trials to encompass the biopsychosocial scope of the review. Included were: (1) randomized controlled trials (RCTs), prospective and retrospective cohort studies, and pharmacovigilance reports evaluating the oral-systemic side effects of GLP-1 RAs; (2) studies detailing the implementation, accuracy, or efficacy of digital health technologies (IoT, AI diagnostics, teledentistry) in dental or metabolic care; and (3) health economics and socio-behavioral analyses focusing on oral health-related quality of life (OHRQoL) and occupational presenteeism. Excluded from the review were non-peer-reviewed preprints, isolated case reports lacking systemic context, editorial commentaries without empirical data, and studies published in languages other than English.

The initial database search yielded a total of 142 potentially relevant sources. Following the removal of duplicates using reference management software, the remaining articles underwent a rigorous two-phase screening process. First, titles and abstracts were independently screened for relevance against the eligibility criteria. Subsequently, full-text reviews were conducted for the shortlisted articles to confirm their applicability to the intersection of pharmacotherapy, social technology, and health economics. Any discrepancies regarding article eligibility were resolved through discussion and consensus among the reviewing authors. Ultimately, 34 sources met all inclusion criteria and were selected for high-level synthesis.

Given the highly interdisciplinary nature of the selected literature—spanning endocrinology, restorative dentistry, biomedical engineering, and health economics—a quantitative meta-analysis was deemed inappropriate due to the heterogeneity of the study designs, varied patient populations, and diverse outcome measures. Consequently, a thematic narrative synthesis approach was employed. Extracted data were systematically coded and categorized into three primary analytical domains aligning with the research questions: (a) the clinical and histomolecular pathophysiology of GLP-1 RA-induced oral dysfunction; (b) the secondary psychosocial and macroeconomic impacts, specifically health capital depreciation; and (c) the structural utility and implementation barriers of digital health interventions.

## 3. Results

### The Clinical and Sensory Ramifications of GLP-1 RAs: A Catalyst for Oral Deterioration

The primary clinical concern regarding the administration of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lies in their complex, and often underreported, interaction with the salivary gland architecture. From a pathophysiological perspective, the disruption of oral homeostasis is initiated at the cellular level. Current histomolecular evidence indicates that GLP-1 receptors (GLP-1R) are actively expressed in both human salivary acinar and ductal cells [9]. The pharmacological activation of these receptors by agents such as semaglutide or tirzepatide modulates intracellular cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) signaling pathways. This cascade directly down-regulates the expression and apical trafficking of aquaporin-5 (AQP5), a transmembrane water channel protein that is fundamentally essential for the secretion of primary saliva [10]. Consequently, the physiological fluid transport mechanism is compromised. Clinical and pharmacovigilance data suggests that a significant percentage of patients undergoing incretin therapy experience subjective xerostomia alongside gastrointestinal discomfort [11].

However, the clinical implications extend far beyond the mere subjective sensation of oral dryness. Objective hyposalivation—characterized by a clinically significant decrease in the un-stimulated and stimulated salivary flow rate (SFR)—precipitates a critical depletion of the protective salivary proteome [12]. This depletion creates a highly vulnerable and potentially cariogenic oral environment. Specifically, the reduction in high-molecular-weight mucins, such as MUC5B and MUC7, compromises the formation of the acquired enamel pellicle, thereby reducing mucosal lubrication and increasing the tribological wear of dental tissues. Furthermore, the diminished concentration of bicarbonate ions ($HCO3^-$) removes the oral cavity's primary buffering system against acidic challenges. Without this buffer, the intra-oral pH drops more rapidly and remains below the critical threshold of 5.5 for extended periods, fundamentally altering the dynamics of the Stephan curve [13]. Coupled with a diminished availability of calcium ($Ca2+$) and phosphate ($PO43^-$) ions, the natural thermodynamic cycle of enamel remineralization is effectively stalled, accelerating the demineralization of hydroxyapatite crystals.

This localized state of compromised oral defense is severely exacerbated by the systemic mechanisms of GLP-1 RAs, most notably the targeted delay of gastric emptying [14]. While the deceleration of gastrointestinal motility is a highly beneficial mechanism for mitigating postprandial glucose spikes and promoting early satiety, it frequently induces secondary gastroesophageal reflux disease (GERD). The episodic regurgitation and exposure of the oral cavity to endogenous gastric hydrochloric acid introduces a severe chemical insult. This phenomenon creates a "double-hit" clinical scenario: the dental hard tissues are subjected to a highly aggressive endogenous acid attack precisely when the salivary buffering and clearance mechanisms are pharmaceutically suppressed. This synergy precipitates perimylolysis—the rapid, widespread, and irreversible chemical dissolution of enamel, primarily affecting the palatal surfaces of the maxillary dentition [4].

The complex interplay between systemic GLP-1 RA administration, salivary gland dysfunction, and secondary gastric reflux is illustrated in Figure 1.




***Fig. 1.*** *Pathophysiological mechanisms of oral complications induced by GLP-1 receptor agonist (GLP-1 RA) therapy.*

In addition to profound structural degradation, incretin-based therapies significantly modulate sensory perception within the oral cavity. While GLP-1 RAs primarily act upon the central nervous system to regulate appetite, GLP-1 receptors are also localized on Type II taste bud cells, which are responsible for sweet, bitter, and umami perception. The systemic activation of these receptors frequently induces dysgeusia, with patients often exhibiting an altered detection threshold for sweet stimuli [5]. In a strictly clinical paradigm, dysgeusia is often categorized as a minor adverse event. However, within a broader biopsychosocial framework, this sensory modulation fundamentally alters the hedonistic value of food consumption. Because dining and sharing meals are foundational human social activities, drug-induced dysgeusia—combined with the physical discomfort of xerostomia and potential halitosis—can precipitate profound dietary behavioral changes, social withdrawal, and a measurable deterioration in the patient's overall quality of life (QoL) [15].

This psychological burden underscores the necessity of moving beyond traditional biomedical paradigms to embrace the broader biopsychosocial model first articulated by Engel, which integrates biological disruptions with their psychological and social consequences [6]. The distress stemming from persistent oral dryness, functional discomfort, and altered taste can easily trigger or exacerbate generalized anxiety, a state often quantified by clinical tools such as the GAD-7 [16]. Furthermore, the profound intersection between emotional well-being and stomatognathic function reinforces the established psychiatric maxim that there can be no true mental health without oral health [31]. A comprehensive conceptual framework for measuring oral health must therefore account for these multidimensional impairments, recognizing that physical symptoms invariably cascade into psychological distress [32].

Beyond the psychosocial dimension, the localized oral deterioration induced by GLP-1 RAs presents a paradoxical risk to the patient's broader metabolic health. The target demographic for agents like semaglutide typically comprises individuals managing the complex global etiologies of type 2 diabetes mellitus and clinical obesity [1, 2]. While these therapeutics offer proven cardiovascular benefits [30] and mediate significant weight loss, the drug-induced hyposalivation creates an environment highly susceptible to periodontal disease. Extensive scientific consensus confirms a bidirectional relationship between periodontitis and diabetes, where systemic inflammation from oral dysbiosis actively impairs glycemic control [27]. Consequently, if incretin-based therapies inadvertently catalyze periodontal breakdown, the resulting oral inflammation could systemically counteract the very metabolic improvements the drugs are prescribed to achieve. Conversely, proactive periodontal therapy has been shown to significantly improve general health outcomes and reduce systemic complications [34].

Addressing this complex interaction requires a profound shift in clinical management, effectively overcoming the historical separation between medical and dental health care to promote robust interprofessional collaboration [25]. Oral diseases already represent a massive global public health challenge [17], carrying a severe economic impact [18]. However, evidence clearly demonstrates that integrating preventative dental care into the management of diabetic patients not only improves clinical outcomes but also substantially reduces overall medical care costs [19]. This economic and clinical synergy perfectly aligns with the principles of value-based healthcare, which prioritizes the maximization of patient health outcomes relative to the cost of care [26]. Investing in preventive oral hygiene acts as a fundamental form of "health capital," a concept highlighting that health is an endogenous asset demanding continuous maintenance to prevent accelerated depreciation [7].

To effectively mitigate the oral adverse effects of GLP-1 RAs, modern healthcare must leverage emerging digital and diagnostic technologies. The integration of teledentistry has proven highly effective in maintaining continuous patient surveillance, particularly during periods when traditional access to care is compromised [8, 23]. Additionally, artificial intelligence and deep learning algorithms are rapidly transforming diagnostic dentistry, allowing for the early radiographic detection of apical lesions and structural anomalies before they manifest clinically [22, 33]. At the forefront of personalized monitoring, wearable cellulose acetate-coated mouthguard biosensors now enable continuous *in vivo*salivary glucose measurement, offering a non-invasive mechanism to track physiological changes in real-time [20]. However, the successful implementation of these eHealth interventions requires adequate digital health literacy among patients [28] and careful navigation of social health inequalities to ensure equitable access across diverse populations [24]. Furthermore, the continuous collection of salivary and biometric data necessitates strict adherence to privacy regulations to protect sensitive health information [21]. Ultimately, by combining interprofessional collaboration with advanced digital monitoring, clinicians can preemptively manage the oral ramifications of GLP-1 RAs, ensuring that the remarkable systemic benefits of these therapies are not undermined by preventable stomatognathic decline. A comprehensive summary of the primary clinical manifestations and targeted diagnostic-therapeutic recommendations for this patient population is provided in Table 1.

**Table 1.** Clinical manifestations and diagnostic-therapeutic recommendations for patients on GLP-1 RA therapy

| CLINICAL AREA | MANIFESTATION AND DIAGNOSTIC RISK | INTERVENTIONS AND CLINICAL RECOMMENDATIONS |
|---|---|---|
| **SALIVARY SECRETION** | Hyposalivation (SFR < 0.1 ml/min); subjective burning and dryness of mucous membranes. | Use of saliva substitutes (mucin-based); education regarding forced fluid intake. |
| **HARD TISSUES** | Perimylolysis (palatal erosion); rapid progression of erosive-carious lesions. | Fluoride pastes (5000 ppm); professional fluoridation every 3 months; alkaline pH rinses after reflux episodes. |
| **TASTE PERCEPTION** | Dysgeusia (metallic taste); change in sensitivity thresholds for sweet/bitter stimuli. | Monitoring changes in eating habits; avoiding irritating alcohol-based rinses. |
| **PERIODONTIUM/ IMPLANTS** | Accumulation of pathogenic biofilm; risk of peri-implantitis with coexisting nicotinism. | Shortening of hygiene visit intervals (recall every 3–4 months); intensification of plaque control. |

**The Socio-Economic Architecture of Oral Health Deterioration**

The transition from a strictly clinical evaluation of GLP-1 receptor agonists to a comprehensive social science perspective requires fundamentally redefining oral health. Within the context of modern interdisciplinary care, oral health must not be viewed merely as the absence of stomatological disease, but rather as a critical component of an individual's "Social Capital" and "Health Capital." According to Grossman's foundational health production function model [7], health is a durable capital stock that depreciates over time but can be maintained through strategic investments. In the case of patients undergoing incretin therapy, the iatrogenic acceleration of dental erosion and xerostomia fundamentally alters the depreciation rate of their health capital. If this rapid localized deterioration is not countered with prophylactic interventions, it begins to generate profound secondary consequences that ripple through the patient's psychosocial architecture and macroeconomic productivity.

This accelerated depreciation is rooted in the complex physiology of GLP-1 receptors, which are not limited to the gastrointestinal tract but are also expressed in the salivary glands and taste buds [3, 5]. The physiological role of GLP-1 in modulating sweet taste sensitivity [5] and its impact on the autonomic nervous system's control of salivary flow [10] suggest that pharmacological stimulation may directly interfere with the protective mechanisms of the oral cavity. Saliva is the primary biological buffer; its flow rate and composition are essential for maintaining a pH-neutral environment and facilitating the remineralization of hard tissues [12]. When GLP-1 receptor agonists (GLP-1 RAs) induce hyposalivation or alter the salivary proteome [9], the "Stephan curve"—which describes the rapid drop and gradual recovery of plaque pH after carbohydrate consumption [13]—remains in the critical demineralization zone for extended periods. This biochemical shift transforms the oral environment into a niche for acidogenic bacteria, accelerating the transition from health to chronic disease state.

From a psychological and sociological standpoint, the oral cavity is intrinsically linked to the "social self." It is the primary anatomical interface for communication, emotional expression, and communal dining. Chronic xerostomia and drug-induced perimylolysis frequently manifest in secondary clinical signs such as persistent halitosis, phonetic difficulties, and visible aesthetic degradation of the anterior dentition. Empirical studies in behavioral health sciences utilizing diagnostic tools like the Generalized Anxiety Disorder (GAD-7) scale [16] consistently indicate that individuals with perceived poor oral health exhibit significantly higher anxiety scores, social withdrawal, and depressive symptomatology [17, 31]. For the typical GLP-1 RA patient—who is often already navigating the complex psychological burdens and societal stigmas associated with morbid obesity or chronic T2DM [2]—the sudden onset of irreversible dental deterioration acts as a severe, synergistic psychosocial stressor. The resulting embarrassment and physical discomfort frequently lead to the avoidance of social dining and public speaking, thereby precipitating social isolation and a measurable decline in health-related quality of life (HRQoL), as quantified by the Oral Health Impact Profile [15, 32].

The integration of the biopsychosocial model, as proposed by Engel [6], is therefore essential to understand the full scope of pharmacological side effects. The clinical manifestation of gastroesophageal reflux, often exacerbated by the delayed gastric emptying common in GLP-1 therapy [14], leads to direct chemical erosion of the teeth [4]. This is not merely a dental issue; it is a breakdown of the systemic-oral barrier. Historical separations between oral and general healthcare have historically marginalized dental health as an "elective" luxury [25], yet the global public health challenge of oral diseases [17] demands a shift toward value-based healthcare [26]. In this framework, "value" is defined as the health outcomes achieved per dollar spent, which, in the context of GLP-1 therapy, must include the prevention of oral dysfunction to avoid neutralizing the systemic gains in metabolic health.

Beyond the psychological dimension, this localized physiological deterioration translates into substantial macroeconomic friction. In the realm of occupational health, dental morbidity is recognized as one of the leading drivers of "presenteeism"—a phenomenon where an employee is physically present at the workplace but operates at a significantly reduced cognitive and operational capacity due to chronic pain, distraction, or discomfort. The rapid progression of cervical caries, pulpal inflammation, and dentinal hypersensitivity associated with the unbuffered acidic oral environment of a GLP-1 RA patient inevitably disrupts sustained labor productivity. This loss of daily operational efficiency, combined with increased absenteeism required for emergency dental interventions, systematically depletes the patient's capacity to generate economic value and contributes massively to the indirect costs of dental diseases on a global scale [18].

It is crucial to emphasize that presenteeism in this patient cohort is not merely a consequence of acute pain, but rather a complex manifestation of rapid health capital depreciation [7]. Chronic dentinal hypersensitivity, a direct result of unbuffered perimylolysis, acts as a persistent cognitive distractor. It forces

the employee into a state of continuous self-regulation and adaptation to physical discomfort, significantly depleting the attentional resources required for executing precise professional tasks. This mechanism is profoundly amplified in a modern, communication-driven economy, where the oral cavity serves as a primary anatomical instrument for building social capital. The aesthetic degradation of the anterior dentition, coupled with xerostomia-induced phonetic disturbances, often causes the patient—despite being physically present in the workplace—to withdraw from active participation in negotiations, presentations, or collaborative teamwork. Such avoidance behavior, intrinsically driven by the fear of negative social evaluation, serves as a direct illustration of the premise that comprehensive mental well-being and sustained occupational efficiency are unattainable without stable oral health [31]. Consequently, the hidden macroeconomic costs of presenteeism among patients utilizing GLP-1 RAs may easily surpass the direct, out-of-pocket expenditures for reactive dental treatments, constituting a substantial and unmeasured burden on global economic productivity [18].

To mitigate these losses, the healthcare system must embrace disruptive technologies that bridge the gap between diabetology and dentistry. The rise of e-health and teledentistry, accelerated during the COVID-19 pandemic [8, 23], offers a pathway for continuous monitoring of patients on high-risk medication regimens. Innovations such as wearable biosensors for salivary glucose measurement [20] and artificial intelligence for early radiographic detection of lesions [22, 33] could allow for real-time adjustments in prophylactic care. However, the implementation of such tools requires high levels of e-health literacy among patients [28] and robust frameworks for protecting health information [21]. Without addressing the social inequalities in e-health access [24], the technological solution may inadvertently widen the health gap for vulnerable populations.

Consequently, evaluating the true efficacy of GLP-1 RAs requires a more holistic cost-benefit analysis (CBA). While the systemic economic benefits of these medications are undeniable—primarily through the dramatic reduction in long-term hospitalizations for cardiovascular events, neuropathies, and renal failure [30]—these macroeconomic gains are simultaneously being offset by an emergent microeconomic burden. The direct costs associated with rehabilitating an oral cavity devastated by rapid-onset perimylolysis (often requiring high-frequency endodontic treatments, complex prosthodontic reconstructions, and implantology) represent a massive out-of-pocket financial shock for the patient. Current health economic research clearly demonstrates that integrating preventive dental care into diabetes management significantly lowers overall medical care costs [19, 34]. If the pharmaceutical and medical industries continue to scale the administration of GLP-1 RAs without simultaneously integrating structural oral health prophylaxis into the standard care protocol, the celebrated systemic healthcare savings will be partially neutralized by the exponential rise in the economic and social burden of untreated dental disease.

**Bridging the Biopsychosocial Gap Through Digital Health Innovations**

The traditional, siloed architecture of healthcare delivery—where metabolic management and stomatological care operate as mutually exclusive financial and clinical domains—is demonstrably inadequate for addressing the complex, multi-systemic side effects of GLP-1 receptor agonists. To mitigate the localized oral deterioration and the subsequent socio-economic fallout detailed in previous sections, a paradigm shift toward integrated, digitally-mediated care is urgently required. Innovative digital health interventions (DHIs) provide the critical technological bridge connecting the diabetologist's prescription pad with the dentist's prophylactic chair, transforming reactive dental treatments into proactive, algorithmic prevention.

At the vanguard of this technological integration is the deployment of mobile health (mHealth) ecosystems coupled with advanced intra-oral wearable biosensors. The future of monitoring GLP-1 RA-induced xerostomia relies on the transition from subjective patient reporting to objective, continuous telemetry. Recent advancements in biocompatible polymers and microelectromechanical systems (MEMS) have made the development of miniaturized salivary biosensors technologically viable. These devices, integrated into dental splints or mouthguards, can continuously monitor the salivary fluid and dynamic intra-oral variations in real-time [20]. By utilizing Internet of Medical Things (IoMT) protocols, these sensors can transmit data directly to a patient's smartphone. If the algorithmic analysis detects that the intra-oral pH has dropped into the critical cariogenic zone (below 5.5) due to an unbuffered reflux episode, the mHealth application triggers an immediate behavioral nudge—such as a haptic alert prompting the patient to utilize a neutralizing salivary substitute. However, the implementation of such continuous biomonitoring architectures necessitates rigorous socio-technical design, particularly concerning data governance. The secure transmission and storage of continuous physiological data must strictly adhere to international privacy frameworks, including the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act

(HIPAA) in the United States, to prevent the erosion of patient trust and ensure systemic compliance [21]. Beyond immediate clinical utility, this sensor-driven, preventive model aligns fundamentally with the principles of value-based health care, which defines value as the health outcomes achieved per dollar spent [26]. By pre-empting severe stomatological complications linked to GLP-1 RA-induced salivary dysfunction, digital triage ecosystems can significantly mitigate the staggering global economic impact of dental diseases [18]. Retrospective analyses already indicate that establishing robust dental care pathways for patients with diabetes is associated with improved overarching clinical outcomes and substantial reductions in total medical care costs [19]. Thus, integrating real-time oral biomonitoring into metabolic care protocols is not merely a clinical enhancement, but a vital economic stratagem to alleviate the financial burden on healthcare infrastructures.

Transitioning from continuous physiological monitoring to early morphological detection, Artificial Intelligence (AI) presents a revolutionary modality for cross-disciplinary screening. Specifically, the application of Computer Vision (CV) architectures driven by deep Convolutional Neural Networks (CNNs) offers unprecedented diagnostic acuity in identifying iatrogenic enamel degradation. By training these complex deep learning models on annotated intra-oral optical scans, AI algorithms can accurately classify and detect sub-clinical caries and micro-erosions long before they become visually perceptible to a human clinician [25]. The true innovative potential of this technology lies in its deployment outside the dental clinic. Integrating user-friendly, AI-driven smartphone diagnostic tools into primary care or endocrinology clinics allows the prescribing physician to perform a rapid, automated oral screening before initiating GLP-1 RA therapy. This creates a highly efficient, automated triage system that facilitates immediate referrals to dental specialists the moment micro-structural anomalies are detected. The efficacy of such automated diagnostic frameworks, however, is heavily reliant on the robustness of their underlying neural architectures. Deep learning algorithms have already demonstrated profound success in radiographic assessments, such as the automated detection of apical lesions [33]. Yet, as AI permeates primary care screening, several inherent challenges emerge. The successful transition of AI from controlled laboratory environments to diverse clinical settings requires overcoming the "black box" nature of deep learning, ensuring algorithms are interpretable, transparent, and trained on highly heterogeneous datasets to prevent algorithmic bias [22]. Without rigorous external validation, integrating AI tools for GLP-1 RA patients risks yielding false positives that could overwhelm dental referral networks, or worse, false negatives that leave progressive acid erosion unchecked.

Furthermore, the implementation of teledentistry serves as a vital social technology, democratizing access to specialized prophylactic care [23]. For geographically isolated, rural, or socio-economically disadvantaged populations, traditional dental visits are often prohibitively expensive or logistically inaccessible. Remote asynchronous and synchronous teledental consultations allow for critical "anticipatory guidance." Before a patient administers their first dose of semaglutide, a teledental session can deliver personalized education regarding the "saliva-friendly" dietary modifications necessary to survive incretin therapy. Nevertheless, evaluating these digital interventions through a sociological lens requires acknowledging the inherent barriers to technological adoption. A significant demographic of T2DM patients comprises the geriatric population, a group historically vulnerable to the "Digital Divide." Lower levels of digital health literacy, combined with potential cognitive or visual impairments, may render sophisticated mHealth apps or AI smartphone cameras unusable for these individuals, potentially exacerbating existing social health inequalities [24]. Therefore, the successful integration of these technologies mandates an inclusive, human-centered design approach. To systematically bridge this divide, clinicians must preemptively evaluate a patient's capacity to engage with these technologies using validated instruments such as the eHealth Literacy Scale (eHEALS) [28]. Tailoring digital interventions based on individual eHEALS scores ensures that technological tools match the patient's baseline competency level. Furthermore, augmenting these specialized applications with ubiquitous, low-barrier digital platforms—such as structured health communication initiatives deployed via social media—can enhance patient engagement and foster supportive online communities across diverse demographic strata [29]. Ultimately, the technological marvel of biosensors and deep learning models can only fulfill their biopsychosocial mandate if they are embedded within a collaboratively designed framework that actively addresses both the physiological and social determinants of health.

### Public Health Policy and eHealth Literacy: Overcoming the Dental-Medical Divide

The rapid, mass-scale adoption of GLP-1 receptor agonists has exposed a profound structural vulnerability within modern healthcare systems: the historical bifurcation of medical and dental care. Traditionally, public health policies and insurance frameworks have treated "the body" and "the mouth" as separate financial, clinical, and administrative entities [25]. This systemic "dental-medical divide" is acutely detrimental to patients undergoing incretin therapy. While the pharmacological management of metabolic syndrome is typically fully subsidized or heavily supported by national health services and private insurers, the prophylactic and restorative dental care required to manage the iatrogenic fallout of these same drugs is frequently excluded from basic coverage. Consequently, the financial burden of drug-induced perimylolysis and xerostomia is disproportionately shifted onto the patient, transforming a physiological complication into an issue of health equity and socio-economic disparity.

To rectify this systemic oversight, a paradigm shift toward Value-Based Healthcare (VBHC) is imperative. According to the foundational principles of VBHC, health systems must focus on maximizing patient outcomes per unit of cost across the entire cycle of care, rather than optimizing siloed interventions [26]. In this context, health policy must evolve to recognize that comprehensive metabolic management cannot safely exist in isolation from stomatological oversight. We propose the implementation of a mandatory, integrated "Diabeto-Dental Care Pathway." Drawing upon the progressive frameworks established by international consensus reports—which strongly advocate for the integration of periodontal and metabolic care guidelines [27]—a similar policy must be codified for patients initiating GLP-1 RAs. Public health authorities should officially classify "incretin-induced severe xerostomia" as a legitimate, compensable medical complication. Under this proposed policy, an Oral Health Assessment (OHA) would become a mandatory prerequisite for the continuation of incretin prescriptions, entitling patients to subsidized prophylactic interventions (e.g., prescription-strength high-fluoride varnishes) and mitigating the necessity for catastrophic out-of-pocket restorative expenditures later in the treatment cycle.

However, structural policy changes remain insufficient if they are not coupled with a radical enhancement of patient empowerment through health literacy. Currently, a significant systemic communication failure exists: many patients initiating therapies with semaglutide or tirzepatide view these agents primarily as isolated "weight-loss injections," remaining entirely unaware of the potential for rapid dental deterioration. In the digital age, addressing this cognitive gap requires advancing beyond traditional printed pamphlets to foster robust "eHealth Literacy"—the ability to seek, find, understand, and appraise health information from electronic sources to solve a health problem [28]. Public health campaigns must proactively address the concept of the drug-compromised oral environment within the very digital spaces where patients seek medical information. Utilizing digital storytelling, targeted social media micro-learning modules, and interactive health communication strategies can effectively educate patients on the subtle, early signs of hyposalivation and dysgeusia [29]. By elevating eHealth literacy, the healthcare system empowers patients to shift from passive recipients of pharmaceutical interventions to proactive advocates for their own interdisciplinary care, ensuring they have the knowledge and confidence to demand integrated dental oversight from their prescribing physicians.

## 4. Discussion: Synthesizing the Biopsychosocial Paradigm and Future Research Directions

### The Clinical-Systemic Paradox in Modern Diabetology

The synthesis of current literature elucidates a critical lacuna in the contemporary management of obesity and type 2 diabetes mellitus (T2DM). Over the past decade, the medical community has witnessed a revolution in metabolic care. While the systemic metabolic and cardiovascular efficacy of GLP-1 receptor agonists is indisputable—as evidenced by landmark, multi-center trials demonstrating significant, life-saving reductions in major adverse cardiovascular events (MACE) [30]—the unprecedented global scale of their administration has unmasked a secondary, localized epidemic of oral health deterioration. This review has established that the pharmacological suppression of salivary flow and the induction of a highly acidic oral environment create a severe pathophysiological crisis.

However, a profound clinical paradox currently exists: the very medications effectively resolving systemic metabolic crises are simultaneously acting as catalysts for irreversible stomatological destruction. Diabetologists and endocrinologists, rigorously trained to prioritize macrovascular and microvascular endpoints (such as retinopathy, nephropathy, and myocardial infarction), frequently overlook the oral cavity. This systemic blind spot is an artifact of the historical bifurcation of medical and dental disciplines. Consequently, the primary contribution of this analysis lies not merely in identifying the biochemical pathways

of GLP-1 RA-induced xerostomia, but in translating these clinical manifestations into the broader domains of social science, health economics, and digital innovation. As established in psychosomatic medicine, there is "no mental health without oral health" [31]. Thus, the iatrogenic erosion of dental hard tissues and the sensory disruption of dysgeusia must be elevated from the status of "minor adverse events" to primary threats against patient well-being, acting as profound catalysts for psychosocial distress, social withdrawal, and macroeconomic presenteeism.

**Deconstructing the Psychosocial and Behavioral Fallout (Hypothesis 1)**

Current clinical care models are fundamentally ill-equipped to address this intersectional challenge. To bridge this divide and operationalize the socio-technological solutions proposed in this review, we formulate three interdisciplinary research hypotheses to govern the next phase of academic inquiry.

**Hypothesis 1 (Socio-Behavioral Dynamics):** Grounded in Locker's conceptual framework of oral health-related quality of life [32], we hypothesize that patients initiating GLP-1 RA therapy who develop chronic objective hyposalivation will demonstrate a statistically significant longitudinal deterioration in "Social Connectedness" metrics and elevated anxiety scores, driven by dining avoidance and halitosis, when compared to a matched control cohort managing T2DM with non-incretin therapies.

To fully grasp the gravity of this hypothesis, one must deconstruct Locker's model, which elegantly maps the linear progression from physiological impairment to social handicap [32]. In the context of GLP-1 RAs, the physiological *impairment* (pharmacologically suppressed AQP5 channels resulting in reduced salivary flow) rapidly translates into functional *limitation* (difficulty masticating and swallowing dry foods due to lack of mucins). This localized discomfort inevitably escalates into psychological and social *disability*. Patients frequently report profound embarrassment associated with halitosis—a direct consequence of the disrupted oral microbiome and unchecked pathogenic biofilm proliferation. Because communal dining is a foundational pillar of human social integration, the convergence of dysgeusia (altered taste perception) and the mechanical difficulties of eating drives patients toward dietary isolation. The irony is stark and psychologically damaging: a patient may successfully shed significant body weight and improve their HbA1c, thereby overcoming the societal stigma of obesity, only to be immediately subjected to the deep psychological stigma associated with visible dental decay, phonetic difficulties, and bad breath. This transition from metabolic triumph to stomatological shame represents a severe crisis of identity and mental health that current diabetology protocols completely ignore.

**The Implementation Science of Digital Diagnostics (Hypothesis 2)**

To intercept this biopsychosocial decline, the integration of digital health interventions is not merely an option, but a structural necessity.

**Hypothesis 2 (Digital Diagnostic Efficacy):** The proactive integration of Artificial Intelligence-driven Computer Vision (CV) screening tools—building upon established deep learning architectures for radiographic and optical dental diagnostics [33]—within primary endocrinology care will increase the early detection of non-cavitated palatal micro-erosions by at least 40%. Consequently, this intervention will correlate with a measurable reduction in the necessity for complex prosthodontic rehabilitations over a 24-month period.

The theoretical foundation of this hypothesis relies on shifting the diagnostic burden away from the over-extended dental specialist and placing it into the hands of the prescribing physician, mediated by AI. As demonstrated in previous dental AI research, deep neural networks, particularly Convolutional Neural Networks (CNNs), possess a highly superior capacity to detect pixel-level anomalies in enamel morphology that evade the naked human eye **[33]**. However, the true innovation proposed here lies in implementation science. If a diabetologist is equipped with a smartphone-based, AI-driven optical scanner, the oral health assessment becomes a seamless, 30-second addition to the standard metabolic check-up. The AI algorithm effectively acts as an "expert in the loop," objectively quantifying the risk of perimylolysis before the patient experiences any subjective pain or visible cavitation. By identifying these micro-erosions at the absolute earliest stage, the intervention is shifted from highly invasive, expensive restorative dentistry (e.g., crowns, root canals, implants) to minimally invasive, low-cost preventive measures (e.g., prescription of remineralizing pastes and high-concentration fluoride varnishes). This technological bridge effectively democratizes specialized dental triage, though future research must rigorously evaluate the user-interface design and the willingness of physicians to adopt additional screening tools within their already constrained clinical workflows.

**Health Economics and Value-Based Policy Restructuring (Hypothesis 3)**

The adoption of such technological interventions ultimately depends on demonstrating clear, systemic economic viability to healthcare stakeholders and insurance providers.

**Hypothesis 3 (Health Economics and Policy):** Implementing a Value-Based Healthcare (VBHC) model that subsidizes prophylactic oral interventions for patients on incretin therapy will yield a lower "Total Cost of Care." As demonstrated by historical insurance data where periodontal therapy significantly reduced overall medical costs for diabetic patients [34], the initial increase in prophylactic subsidization will be economically offset by the drastic reduction in emergency dental interventions and preserved occupational productivity.

This economic hypothesis addresses the core financial friction of modern healthcare. Currently, national health systems and private insurers operate under a fundamentally flawed, short-term economic paradigm. They readily cover the high costs of GLP-1 RAs due to the predictable long-term savings associated with preventing heart attacks and strokes. However, they systematically refuse to subsidize the preventative dental care required to manage the side effects of these exact drugs. Jeffcoat's landmark analysis of insurance data provided undeniable proof that when insurers pay for preventative dental care (in that specific case, periodontal therapy), the overall medical costs for treating systemic conditions like diabetes drop dramatically [34]. We argue that the identical economic principle applies to GLP-1 RA-induced xerostomia. While subsidizing advanced salivary substitutes, teledental consultations, and AI diagnostics requires an upfront financial investment from the insurer, this cost is exponentially smaller than the downstream financial catastrophe of rehabilitating a fully eroded adult dentition. Furthermore, when factoring in the indirect costs of dental disease—specifically, the massive loss of macroeconomic productivity due to presenteeism and absenteeism caused by chronic dental pain—the Value-Based argument becomes undeniable. Future health-economic modeling must aim to quantify these exact cost-offsets, providing policymakers with the hard fiscal data required to officially mandate the "Diabeto-Dental Care Pathway."

**Limitations of the Current Synthesis**

While this review establishes a robust theoretical and interdisciplinary framework, it is imperative to acknowledge its inherent limitations. The primary limitation is the current scarcity of long-term, multi-center randomized controlled trials (RCTs) specifically designed with dental primary endpoints in populations using GLP-1 RAs. Much of the current data relies on pharmacovigilance databases and retrospective cohort analyses, which are susceptible to reporting bias and confounding variables. Furthermore, the rapid pace of digital health innovation means that the AI and mHealth technologies proposed herein are in continuous states of evolution; regulatory hurdles regarding data privacy (GDPR/HIPAA) and algorithmic bias remain significant challenges that could delay clinical implementation. Finally, the socio-economic models proposed are highly dependent on the structure of specific national healthcare systems, and the economic benefits may not translate uniformly across diverse global insurance landscapes.

Despite these limitations, the validation of the hypotheses presented herein through future empirical research is not merely an academic exercise. Addressing the oral-systemic axis of GLP-1 RA therapy remains a fundamental prerequisite for maintaining the socio-economic vitality, psychological dignity, and overall health capital of the modern metabolic patient.

## 5. Conclusion: Redefining the Standard of Care for the Modern Metabolic Patient

The advent and mass-scale deployment of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) unequivocally represent a watershed moment in the global epidemiological battle against obesity and type 2 diabetes mellitus [1]. As demonstrated in landmark clinical trials, the capacity of agents like semaglutide to deliver robust glycemic control alongside unprecedented cardiovascular protection has fundamentally altered the trajectory of metabolic disease management [2, 30]. However, as this comprehensive review has demonstrated, the profound systemic benefits of incretin therapy are currently being achieved at the unacceptable, localized cost of severe deterioration within the oral-systemic axis. The pharmacological mechanisms that ensure systemic metabolic efficacy simultaneously suppress essential salivary gland physiology [10, 12] and induce secondary gastroesophageal reflux [4, 14]. Together, these factors precipitate a highly aggressive, acidic oral environment that leads to the rapid and often irreversible destruction of dental hard tissues [13].

Crucially, within the context of social science, health economics, and the foundational Biopsychosocial Model proposed by Engel [6], this stomatological pathology transcends mere clinical discomfort. Oral diseases are recognized as a massive global public health challenge precisely because of their cascading impact on

human functionality [17]. For the patient undergoing GLP-1 RA therapy, the secondary psychosocial consequences—ranging from drug-induced dysgeusia [5] and halitosis to elevated generalized anxiety [16] and social isolation—highlight a catastrophic failure in holistic patient care. As established in contemporary psychosomatic medicine, the assertion that there is "no mental health without oral health" is not a metaphor, but a clinical reality [31]. Furthermore, this deterioration systematically erodes the patient's "Health Capital" [7], driving massive indirect economic costs through occupational presenteeism, absenteeism, and diminished societal productivity [18].

To mitigate this emerging biopsychosocial crisis, a fundamental paradigm shift is urgently required. The historical bifurcation of medical and dental disciplines has created a systemic blind spot that actively harms patients navigating complex metabolic therapies [25]. This divide must be bridged through the strategic integration of innovative digital health interventions. The deployment of continuous, IoT-enabled wearable salivary biosensors [20], coupled with AI-driven optical screening utilizing deep learning architectures within primary care settings [22, 33], provides the necessary technological infrastructure to shift oral care from a reactive surgical discipline to a proactive, algorithmic science. Moreover, democratizing access to specialized prophylactic care via teledentistry ensures that "anticipatory guidance" reaches vulnerable and geographically isolated populations before irreversible enamel destruction occurs [8, 23].

Ultimately, if the pharmaceutical industry and national public health systems are to ethically scale the administration of GLP-1 RAs, oral health prophylaxis can no longer be viewed as an optional, out-of-pocket patient responsibility. It must be codified into interprofessional healthcare policies. Drawing upon international consensus models that successfully integrated periodontal and diabetological care [27], we argue for the mandatory establishment of a "Diabeto-Dental Care Pathway" anchored in the principles of Value-Based Healthcare (VBHC) [26]. Large-scale insurance data analyses have already conclusively proven that providing preventative dental care to diabetic patients significantly reduces their overall medical costs and hospital admission rates [19, 34]. By subsidizing advanced salivary substitutes, high-fluoride varnishes, and digital diagnostics, health insurers can offset the devastating microeconomic and macroeconomic burdens of incretin-induced dental disease.

Finally, the success of this technological and policy-driven restructuring hinges upon patient empowerment. Elevating eHealth literacy [28] must become a priority in public health communication, ensuring patients understand the full spectrum of drug-induced side effects. By combining digital technological innovation, value-based economic policies, and enhanced patient education, the medical and socio-economic communities can ensure that the metabolic salvation offered by GLP-1 receptor agonists does not inadvertently become a catalyst for irreversible oral, psychological, and economic destruction.

**Acknowledgments**

The authors received no financial support, grants, or sponsorship for the research, authorship, and publication of this article. Additionally, the authors declares no potential conflicts of interest with respect to this work.

## REFERENCES


1. Zheng, Y., Ley, S. H., & Hu, F. B. (2018). Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nature Reviews Endocrinology, 14*(2), 88–98. https://doi.org/10.1038/nrendo.2017.151
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. *New England Journal of Medicine, 384*(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Drucker, D. J. (2022). GLP-1 physiology informs the mechanisms of action of GLP-1 receptor agonists. *Nature Reviews Drug Discovery, 21*(7), 521–543. https://doi.org/10.1038/s41573-022-00438-x
4. Wilder-Smith, C. H., Materna, A., Martig, L., & Lussi, A. (2009). Gastroesophageal reflux, structural erosion of teeth, and salivary function. *Journal of Clinical Gastroenterology, 43*(3), 240–247. https://doi.org/10.1097/MCG.0b013e3181674400
5. Takai, S., Yasumatsu, K., Inoue, M., et al. (2015). Glucagon-like peptide-1 is specifically involved in sweet taste transmission. *The FASEB Journal, 29*(6), 2268–2280. https://doi.org/10.1096/fj.14-265355
6. Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. *Science, 196*(4286), 129–136. https://doi.org/10.1126/science.847460
7. Grossman, M. (1972). On the concept of health capital and the demand for health. *Journal of Political Economy, 80*(2), 223–255. https://doi.org/10.1086/259880
8. Ghai, S. (2020). Teledentistry during COVID-19 pandemic. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14*(5), 933–935. https://doi.org/10.1016/j.dsx.2020.06.029
9. Barać, M., & Roganović, J. (2025). GLP-1 receptor signaling and oral dysfunction: A narrative review on the mechanistic basis of semaglutide-related oral adverse effects. *Biology, 14*(12), 1650. https://doi.org/10.3390/biology14121650
10. Proctor, G. B. (2016). The physiology of salivary secretion. *Periodontology 2000, 70*(1), 11–25. https://doi.org/10.1111/prd.12116
11. Filippatos, T. D., Panagiotopoulos, S. G., et al. (2014). Adverse effects of GLP-1 receptor agonists. *The Review of Diabetic Studies, 11*(3–4), 202–230. https://doi.org/10.1900/RDS.2014.11.202
12. Dawes, C. (2003). Salivary flow patterns and the health of hard and soft oral tissues. *The Journal of the American Dental Association, 134*(5), 561–569. https://doi.org/10.14219/jada.archive.2003.0221
13. Stephan, R. M. (1944). Intra-oral hydrogen-ion concentrations associated with dental caries activity. *Journal of Dental Research, 23*(4), 257–266. https://doi.org/10.1177/002203454402300404
14. Halawi, H., Khemani, D., Eckert, D., et al. (2017). Effects of liraglutide on weight, satiation, and gastric emptying in obese people. *Gastroenterology, 153*(5), 1230–1239. https://doi.org/10.1053/j.gastro.2017.07.028
15. Slade, G. D. (1997). Derivation and validation of the Oral Health Impact Profile. *Community Dentistry and Oral Epidemiology, 25*(4), 284–290. https://doi.org/10.1111/j.1600-0528.1997.tb00941.x
16. Spitzer, R. L., Kroenke, K., Williams, J. B., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. *Archives of Internal Medicine, 166*(10), 1092–1097. https://doi.org/10.1001/archinte.166.10.1092
17. Peres, M. A., Macinko, J., Watt, R. G., et al. (2019). Oral diseases: A global public health challenge. *The Lancet, 394*(10194), 249–260. https://doi.org/10.1016/S0140-6736(19)31146-8
18. Listl, S., Galloway, J., Mossey, P. A., & Marcenes, W. (2015). Global economic impact of dental diseases. *Journal of Dental Research, 94*(10), 1355–1361. https://doi.org/10.1177/0022034515602879
19. Mosen, D. M., Pihlstrom, D. J., Snyder, J. J., & Smith, N. (2016). Association of dental care with clinical outcomes and medical care costs among patients with diabetes. *The Journal of the American Dental Association, 147*(11), 895–903. https://doi.org/10.1016/j.adaj.2016.05.008
20. Arakawa, T., Tomoto, K., Nitta, H., et al. (2020). A wearable cellulose acetate-coated mouthguard biosensor for in vivo salivary glucose measurement. *Analytical Chemistry, 92*(18), 12201–12207. https://doi.org/10.1021/acs.analchem.0c01201
21. Cohen, I. G., & Mello, M. M. (2018). HIPAA and protecting health information in the 21st century. *JAMA, 320*(3), 231–232. https://doi.org/10.1001/jama.2018.5630
22. Schwendicke, F., Samek, W., & Krois, J. (2020). Artificial intelligence in dentistry: Chances and challenges. *Journal of Dental Research, 99*(7), 769–774. https://doi.org/10.1177/0022034520915714
23. Jampani, N. D., Nutalapati, R., Dontula, B. S., & Boyapati, R. (2011). Applications of teledentistry: A literature review and update. *Journal of International Society of Preventive & Community Dentistry, 1*(2), 37–44. https://doi.org/10.4103/2231-0762.97695
24. Latulippe, K., Guay, C., & Giroux, V. (2017). Social health inequalities and eHealth: A literature review with qualitative synthesis. *Journal of Medical Internet Research, 19*(4), e136. https://doi.org/10.2196/jmir.6731
25. Simon, L. (2016). Overcoming historical separation between oral and general health care: Interprofessional collaboration for promoting health equity. *AMA Journal of Ethics, 18*(9), 941–949. https://doi.org/10.1001/journalofethics.2016.18.9.medu1-1609

26. Porter, M. E. (2010). What is value in health care? *New England Journal of Medicine, 363*(26), 2477–2481. https://doi.org/10.1056/NEJMp1011024
27. Sanz, M., Ceriello, A., Buysschaert, M., et al. (2018). Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology. *Journal of Clinical Periodontology, 45*(2), 138–149. https://doi.org/10.1111/jcpe.12808
28. Norman, C. D., & Skinner, H. A. (2006). eHEALS: The eHealth Literacy Scale. *Journal of Medical Internet Research, 8*(4), e27. https://doi.org/10.2196/jmir.8.4.e27
29. Moorhead, S. A., Hazlett, D. E., Harrison, L., et al. (2013). A new dimension of health care: Systematic review of the uses, benefits, and limitations of social media for health communication. *Journal of Medical Internet Research, 15*(4), e85. https://doi.org/10.2196/jmir.1933
30. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *New England Journal of Medicine, 375*(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141
31. Kisely, S. (2016). No mental health without oral health. *The Canadian Journal of Psychiatry, 61*(5), 277–282. https://doi.org/10.1177/0706743716632523
32. Locker, D. (1988). Measuring oral health: A conceptual framework. *Community Dental Health, 5*(1), 3–18.
33. Krois, J., Ekert, T., Meinhold, L., et al. (2019). Deep learning for the radiographic detection of apical lesions. *Journal of Dental Research, 98*(10), 1087–1093. https://doi.org/10.1177/0022034519840228
34. Jeffcoat, M. K., Jeffcoat, R. L., Gladowski, P. A., et al. (2014). Impact of periodontal therapy on general health: Evidence from insurance data for five systemic conditions. *American Journal of Preventive Medicine, 47*(2), 166–174. https://doi.org/10.1016/j.amepre.2014.04.001